Tag Archives: Clinical Research Advantage

DBruggeman

CRA President among life science's most inspiring

Tempe-based Clinical Research Advantage (CRA), the country’s largest wholly owned network of clinical trial sites, announced that the company’s President & Chief Operating Officer,  David M. Bruggeman, has been selected by PharmaVOICE Magazine as one of the 100 most inspiring people in the life sciences industry. Bruggeman, a 30-year healthcare industry veteran, was honored for his vision and innovation in the clinical trials industry.

Since acquiring CRA in 2007, Bruggeman has been the pioneering force behind the development of an integrated platform for clinical research. This platform has allowed CRA to standardize its research procedures and make the trial process safer and more efficient. It has also enabled CRA to expand rapidly – growing from just six sites in Phoenix to more than 60 sites across the country in the past six years.

“David is an inspiring leader who is dedicated to furthering our industry,” said Mark S. Hanley, CRA’s Chief Executive Officer.  “David’s work has improved the quality and efficiency of clinical trials and improved the patient experience. On behalf of the CRA team, I’d like to congratulate David on this well-deserved honor.”

The PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. Nominated by thousands of PharmaVOICE readers, the recipients are selected based on comprehensive essays describing how they have inspired or motivated their colleagues, peers and others; and how they have affected positive change in their organizations or communities. The individuals of the PharmaVOICE 100 represent a broad cross section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, technology and many others.

DBruggeman

CRA President among life science’s most inspiring

Tempe-based Clinical Research Advantage (CRA), the country’s largest wholly owned network of clinical trial sites, announced that the company’s President & Chief Operating Officer,  David M. Bruggeman, has been selected by PharmaVOICE Magazine as one of the 100 most inspiring people in the life sciences industry. Bruggeman, a 30-year healthcare industry veteran, was honored for his vision and innovation in the clinical trials industry.

Since acquiring CRA in 2007, Bruggeman has been the pioneering force behind the development of an integrated platform for clinical research. This platform has allowed CRA to standardize its research procedures and make the trial process safer and more efficient. It has also enabled CRA to expand rapidly – growing from just six sites in Phoenix to more than 60 sites across the country in the past six years.

“David is an inspiring leader who is dedicated to furthering our industry,” said Mark S. Hanley, CRA’s Chief Executive Officer.  “David’s work has improved the quality and efficiency of clinical trials and improved the patient experience. On behalf of the CRA team, I’d like to congratulate David on this well-deserved honor.”

The PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life sciences industry. Nominated by thousands of PharmaVOICE readers, the recipients are selected based on comprehensive essays describing how they have inspired or motivated their colleagues, peers and others; and how they have affected positive change in their organizations or communities. The individuals of the PharmaVOICE 100 represent a broad cross section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, technology and many others.

medical.research

Clinical Research Advantage expands reach

Clinical Research Advantage (CRA), the country’s largest wholly owned network of clinical trial sites, has further expanded its geographic and therapeutic reach by acquiring the late phase division of Comprehensive Clinical Development (CCD). This transaction will allow CRA to offer pharmaceutical sponsors and contract research organizations an across-the-board solution for their diverse clinical research needs.

Clinical Research Advantage includes 63 sites listed under “CRA” and “Radiant Research.” Both brands are known as leaders in Stage II-IV clinical trials. CRA focuses on on family practice and general medicine, while Radiant conducts multi-specialty and consumer trials. Comprehensive Clinical Development is a leader in psychiatric clinical trials, specifically in the areas of schizophrenia, bipolar disorder, depression, and Alzheimer’s disease. CCD has participated in the development of every major psychiatric drug that has been developed over the past 10 years, and it is recognized in the industry as a high quality researcher and successful enroller for psychiatric trials.

“By adding Comprehensive Clinical Development to the CRA family of trial sites we are able to increase our capabilities to meet the needs of the growing pharmaceutical marketplace,” said Mark S. Hanley, Chief Executive Officer of CRA. “We are excited about this partnership and the opportunity to move into new therapeutic areas of clinical research. CCD has an impressive track record in psychiatric trials, and we see it as an ideal partner as we continue to expand our operations.”

Based in Miramar, Fla., CCD was founded in 1998. The company operates four independent sites in Atlanta, Ga., Cerritos, Calif., Holliswood, N.Y., and Washington, D.C. The combined companies will continue to function under the names Clinical Research Advantage and Comprehensive Clinical Development, but will be looking to integrate and streamline their operations where appropriate.

Mark H pics 012

CRA's CEO Wins Gold Stevie Award

Mark S. Hanley, Chief Executive Officer of Clinical Research Advantage, Inc. (CRA), was the recipient of a Gold Stevie® Award in this year’s American Business Awards. Hanley was recognized as the “Maverick of the Year” in the Business Services category.

Hanley was honored for his innovative vision and leadership, which included acquiring Radiant Research in 2012 to create the country’s largest and most therapeutically diverse integrated network of clinical trial sites. “It is an honor to receive this award,” said Hanley. “But, this is really an award for the entire CRA team. It is through all of their hard work and dedication that we have accomplished so much in the past 12 months.”

The American Business Awards are the nation’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. Stevie Award winners were selected by more than 320 executives nationwide who participated in the judging process this year.

Nicknamed the Stevies for the Greek word for “crowned,” the 11th annual award ceremony was held on June 17th in Chicago, Illinois. This year, the judges reviewed more than 3,200 nominations from organizations of all sizes and virtually every industry.

 

Mark H pics 012

CRA’s CEO Wins Gold Stevie Award

Mark S. Hanley, Chief Executive Officer of Clinical Research Advantage, Inc. (CRA), was the recipient of a Gold Stevie® Award in this year’s American Business Awards. Hanley was recognized as the “Maverick of the Year” in the Business Services category.

Hanley was honored for his innovative vision and leadership, which included acquiring Radiant Research in 2012 to create the country’s largest and most therapeutically diverse integrated network of clinical trial sites. “It is an honor to receive this award,” said Hanley. “But, this is really an award for the entire CRA team. It is through all of their hard work and dedication that we have accomplished so much in the past 12 months.”

The American Business Awards are the nation’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. Stevie Award winners were selected by more than 320 executives nationwide who participated in the judging process this year.

Nicknamed the Stevies for the Greek word for “crowned,” the 11th annual award ceremony was held on June 17th in Chicago, Illinois. This year, the judges reviewed more than 3,200 nominations from organizations of all sizes and virtually every industry.

 

DBruggeman

CRA President Receives Stevie Awards

David M. Bruggeman, President and Chief Operating Officer of Clinical Research Advantage, Inc. (CRA), was the recipient of two Stevie Awards at the 11th annual American Business Awards. Bruggeman received the Bronze Award for “Executive of the Year” in both the Pharmaceuticals and Health Products and Services categories.

Bruggeman was recognized for his ingenuity and leadership in building the country’s largest integrated network of clinical trial sites and partnering with Quintiles to create the first-ever therapeutic alliance for clinical trials in primary medicine. “David is an extraordinary leader whose work has improved the quality and efficiency of the clinical research process,” said Mark S. Hanley, CRA’s Chief Executive Officer. “We are happy to hear that David has received this national honor.”

The American Business Awards are the nation’s premier business awards program. All organizations operating in the U.S.A. are eligible to submit nominations – public and private, for-profit and non-profit, large and small. Stevie Award winners were selected by more than 320 executives nationwide who participated in the judging process this year.

Nicknamed the Stevies for the Greek word for “crowned,” the awards were held on June 17th in Chicago, Illinois. This year, the judges reviewed more than 3,200 nominations from organizations of all sizes and virtually every industry.

87665813

Women to watch in healthcare, energy, aerospace and technology

Here are some of the the Arizona innnovators who Az Business magazine thinks will be making waves in healthcare, energy, aerospace and technology in 2013:

Ruth Carter
Owner, Carter Law Firm
carterlawaz.com
Her background: After graduating from ASU Law School in 2011, she opened her own law firm in January 2012 and focused her practice on social media law, intellectual property, business formation and contracts, and flash mob law. She will deliver a talk entitled “Protecting Your Copyrights in Digital Media” at the South By Southwest Interactive (SXSW) in March 2013. She also wrote the book “The Legal Side of Blogging: How Not to get Sued, Fired, Arrested, or Killed.”
Fun fact: She was selected as an American Bar Association Legal Rebel in September 2012.
Her goal for 2013: To help entrepreneurs, writers, and artists turn their ideas into reality, to help them push the limits of what’s possible without crossing the line.

Michelle De Blasi
Shareholder, Greenberg Traurig
gtlaw.com
Her background: De Blasi focuses her practice on environmental law, with an emphasis on natural resources matters. She advises local and multi-national clients on energy and environmental sustainability, including the development of traditional and renewable energy power plants, climate change, and greenhouse gas emissions. She is a leader in many community organizations, including serving as the Co-Chair of the Arizona Energy Consortium, which has recently released the Arizona Energy Roadmap to further develop the state’s energy industry.
Fun fact: “I wanted to be an environmental attorney since junior high.  Working for six years at NOAA starting in law school was an amazing way to begin my career.”
Her goal for 2013: “Continue to assist my clients’ growth and expansion, including improving the regulatory and business atmosphere in the areas where they are located.”

MaryAnn Guerra
CEO, BioAccel
bioaccel.org
Her background: BioAccel was named the most promising initiative among the six winners of SSTI’s 2012 Excellence in TBED (technology-based economic development) awards. In three years, BioAccel — whose mission is to transform high-risk technologies into new businesses and high-wage jobs — has supported 11 companies in Arizona, investing more than $4 million directly as well as helping get an additional $15.5 million in downstream funding.
Fun fact: “I love camping outdoors in tents. After gathering wood from the forest, I  build the campfire, cook, then relax under the moonlight — with wine if possible.”
Her goal for 2013: “Personally: spend more time with my husband.  Professionally: expand BioAccel’s overall capacity, validate BioInspire as a model and help launch the BioAccel Accelerator Fund.”

Chevy Humphrey
President and CEO, Arizona Science Center
azscience.org
Her background: She oversees the $8 million operation of Arizona Science Center’s 185,000-square-foot facilities with more than 400 employees and volunteers. She is in line to become the next president of the Association of Science-Technology Centers, an international organization representing science centers and museums with more than 600 members in over 40 countries worldwide. She currently serves as its secretary-treasurer.
Fun fact: Humphrey secured the largest gift in the Center’s history – $3.5 million.
Her goal for 2013: “Maintain excellence as Arizona’s largest provider of informal science education while providing educators with professional development and resources supporting the new common core education standards.”

Mary Juetten
Founder and CEO, Traklight.com
traklight.com
Her background: While earning her JD at ASU, Juetten combined her new knowledge of the law with accounting designations and 25 years of management, business and financial consulting experience to create Traklight.com in 2010.  Traklight is an online software as service company that offers products for inventors, creators, start-up or small companies to identify, secure, and manage their intellectual property to reduce the risk of infringement and IP loss, all without any prior knowledge of IP.
Fun fact: She played ice hockey in Canada and Phoenix.
Her goal for 2013: “I plan to spend more time outside with my husband: golfing and hiking.  Traklight will build upon our October launch and expand nationally in 2013.”

Kim Kundert
Vice president of clinical operations
Clinical Research Advantage
Her background: Kundert received the 2012 Silver Stevie Award — which honors the world’s bets and brightest female entrepreneurs and executives — for Female Executive of the Year in the Business Services category. Kundert has been a driving force behind the rapid growth of CRA, a clinical trial management organization that has helped trial sponsors bring drugs to market more quickly and efficiently.
Fun fact: She was born in Germany on Christmas Day.
Her goal for 2013: “My goal is to open 20 new clinical trial sites.”

Jessica Langbaum
Principal scientist, Banner Alzheimer’s Institute
banneralz.org
Her background: Langbaum is actively involved in research activities focusing on the use of brain imaging for studying the earliest evidence of Alzheimer’s and on the design and execution of preclinical Alzheimer’s treatment trials. Langbaum has published papers in leading scientific journals on cognitive training, brain imaging and Alzheimer’s disease.
Fun fact: Her family has been in Arizona for generations.
Her goal for 2013: “Enroll 100,000 people in our Alzheimer’s Prevention Registry (endALZnow.org/registry), launch the Alzheimer’s Prevention Initiative (API)/Genentech trial, prepare for the next API-led trial, and potty train my son.”

Paula O’Neal Wichterman
Vice president, medical private banker, National Bank of Arizona
nbarizona.com
Her background: Wichterman is vice president in the Private Bank of National Bank of Arizona. Prior to joining NB|AZ, she spent 9 years in various advisor roles at two other lending institutions in both private banking and credit administration. In her role at NB|AZ, Wichterman is responsible for increasing NB|AZ’s focus on the physician and medical banking market.
Fun fact: “Being the Southern girl that I am, I LOVE to shoot sporting clays. It is a great stress reliever after a long week at work.”
Her goal for 2013: “I want to always inspire my family and friends. I try my best to lead by example. Whether it is at home or at work, I want to be the best that I can be.”

Angela Perez
Partner, Snell & Wilmer
swlaw.com
Her background: Perez is an Arizona native who holds a biology degree from Harvard University and law degree from The University of Arizona. She practices law in the field of business and finance, with special attention to representing clients in the biotechnology industry. Perez represents companies at all stages of their life cycle, from start-up to liquidity. Perez is committed to using her education and experience to improve the strength of Arizona’s economy by facilitating the growth of Arizona’s biotech industry.
Fun fact: Formed Snell & Wilmer’s Bioscience and Healthcare Industry Group shortly after graduating from law school.
Her goal for 2013: “Contribute to the success of my firm and clients by providing sound legal advice; support Arizona’s biotech industry; and shower my young family with love.”

Darcy Renfro
Vice president and coordinator of the Arizona STEM Network, Science Foundation Arizona (SFAz)
sfaz.org
Her background: Renfro is leading the way for Arizona’s STEM — science, technology, engineering, math — education initiatives. She spearheaded the development of SFAz’s Arizona STEM Network, a first-of-its-kind strategic effort to help transform Arizona’s educational system. The Network will help teachers and students prepare for the state-adopted, internationally benchmarked Common Core Standards, higher-education and careers that will help ensure our state remains globally competitive.
Fun fact: Arizona is just one of 16 states in the U.S. with developing or existing STEM Networks.
Her goal for 2013: “Increase the access and quality of STEM opportunities for Arizona’s students and teachers to inspire excitement and achievement in math and science.”

Virginia Rybski
President and CEO, Regenesis Biomedical, Inc.
regenesisbio.com
Her background: Rybski has combined 35 years of experience founding, building and growing emerging bioscience companies by developing and launching numerous advanced-technology, healthcare related products. She strategically positioned the company as a regenerative medicine business; raised $5.3 million in capital; has grows sales for 8 consecutive years; and helped it earn a position on the Inc. 5000 list of the fastest-growing private companies in America in 2012.
Fun fact:
Her goal for 2013: “Focus on improving patient care, and helping to provide better patient outcomes while lowering the overall cost of care. Healthcare, now more than ever, needs collaboration between providers, patients, and manufacturers like Regenesis, to help rein in spiraling costs.”

Joyce Schroeder
Chief science officer, Arizona Cancer Therapeutics
arizonacancertherapeutics.com
Her background: Schroeder, program co-leader in Cancer Biology and Genetics at the Arizona Cancer Center, is moving toward clinical trials for breast cancer treatment that inhibits metastatic breast cancer growth at cellular level and it is non-toxic. In layman’s terms, this could block breast cancer growth without the toxic side effects of chemotherapy. She is also associate professor of molecular and cellular biology at the University of Arizona.
Fun fact: She is an avid Stephen King reader and loves Star Wars.
Her goal for 2013: “My goal for 2013 is to get our breast cancer drug approved by the FDA to be given to patients.”

Lori Singleton
Manager of Sustainability Initiatives and Technologies, SRP
srpnet.com
Her background: Singleton’s primary focus at SRP is environmental and renewable energy issues. Under her direction, SRP has provided incentives to more than 12,000 customers who have installed solar energy systems on their homes and businesses. In addition, she is an active volunteer and effective advocate serving on the boards of Audubon of Arizona and the National Solar Energy Power Association.
Fun fact: “Ballroom dancing is my passion. For me, it not only helps keep me physically fit but allows me to focus on something other than looming deadlines and work projects.”
Her goal for 2013: “As a Valley Forward board member, I will work to promote environmental quality statewide, elevate our state’s image and drive balanced policy as the organization evolves into Arizona Forward.”

Joy Seitz
Vice president of business and policy development, American Solar
americanpv.com
Her background: Since joining Scottsdale-based American Solar in 2009, Seitz has been a leading advocate for Arizona’s solar industry, making her presence felt everywhere that decisions are made about solar energy — city halls, Salt River Project and the Arizona Corporation Commission. Her company has designed and installed solar electric for more than 3,500 customers and created partnership with homebuilders including Shea Homes and AV Homes.
Fun fact: “I am a proud ASU West Campus graduate from the School of Global Management and Leadership, with an emphasis in finance.”
Her goal for 2013: “To put the power of solar energy into the hand of every homeowner. It is time that every Arizona homeowner understands that they can control what energy powers their home.”

Lois Wardell
Principal, Arapahoe SciTech
arapahost.com
Her background: Wardell’s technology focus includes unmanned aerial vehicles (UAVs) and associated sensor technologies.  By developing partnerships with other innovators, she has been able to tackle technical challenges in emerging fields such as those in polar science. One example is a sterilization system for an ice drill that will access an Antarctic sub-glacial lake below a half-mile of ice to explore this unknown frontier on our planet.
Fun fact: Wardell has worked on all seven continents.
Her goal for 2013: “My goals include continued development of technology for exploration (both Earth and beyond) and to increase my focus on outreach activities to inspire students.”

sleep

S.T.A.R.S. Receives Gold Best in Biz Award

Sleep Testing and Respiratory Services (S.T.A.R.S.) received top honors in this year’s Best in Biz Awards, the only independent business awards program judged by members of the press and industry analysts. The company’s Director of Human Resources, Kara Chase, was honored with a Gold Best in Biz Award for Human Resources Executive of the Year.

Chase was recognized for her integral role in the 2011 S.T.A.R.S. asset purchase, and for her leadership and management as head of Human Resources for S.T.A.R.S. and its sister companies, Heartland Health and Clinical Research Advantage.

“Kara Chase has been instrumental in the success of S.T.A.R.S., Heartland Health and Clinical Research Advantage,” said Mark S. Hanley, Chief Executive Officer of S.T.A.R.S. “She was responsible for leading a series of initiatives to safeguard each company as it grew. This enabled us to manage our unprecedented growth while upholding our high standards for quality and service.”

More than 400 entries were received in this year’s awards program, from a wide array of public and private companies of all sizes and from a variety of industries and regions in the U.S. and Canada.

Winners of Best in Biz Awards 2012 were determined by an independent panel of 32 judges from top-tier news, business and technology publications, as well as broadcast outlets and analyst firms, such as ABC, Businessweek, Computerworld, ECT News Network, Entrepreneur, eWeek, Examiner, Financial Times, Forbes, FOX News, Hartford Business Journal, IDG Ventures, IEEE Institute, Inc., Insight Media, King Features Syndicate, Lab Reviews, Network World, The News and Observer, PC Magazine, ReadWriteWeb, South Florida Business Journal, Tech-Gaming, Techtalk, Upstart Business Journal, USA Today and ZDNet.

Vesely

CRA Finance Department earns honors

Clinical Research Advantage’s Finance Department received two national honors in this year’s Best in Biz Awards, the only independent business awards program judged by members of the press and industry analysts. The company received the Silver Award for Finance Executive of the Year and Finance Department of the Year.

Jim Vesely, Chief Financial Officer, and his team of Sandy Zipp, Accountant, and Jan Jacobson, Accounting Associate, were recognized for developing and implementing a metrics system that allowed the company to increase revenue and obtain the capital needed for expansion. CRA experienced rapid growth in 2011 and 2012, becoming largest and most therapeutically diverse integrated site network in the clinical trials industry.

“Jim Vesely and his team have done an extraordinary job. Through their efforts, CRA was able to grow our geographic presence and our employee base at a time when many other businesses in our industry were cutting back,” said Mark S. Hanley, CRA’s Chief Executive Officer. “The awards received by Jim, Sandy and Jan are well deserved.”

More than 400 entries were received in this year’s awards program, from a wide array of public and private companies of all sizes and from a variety of industries and regions in the U.S. and Canada.

Winners of Best in Biz Awards 2012 were determined by an independent panel of 32 judges from top-tier news, business and technology publications, as well as broadcast outlets and analyst firms, such as ABC, Businessweek, Computerworld, ECT News Network, Entrepreneur, eWeek, Examiner, Financial Times, Forbes, FOX News, Hartford Business Journal, IDG Ventures, IEEE Institute, Inc., Insight Media, King Features Syndicate, Lab Reviews, Network World, The News and Observer, PC Magazine, ReadWriteWeb, South Florida Business Journal, Tech-Gaming, Techtalk, Upstart Business Journal, USA Today and ZDNet.

Mark H pics 001

CRA forms alliance with Quintiles

Tempe-based Clinical Research Advantage (CRA), the country’s largest community-based network of clinical trial sites, has entered into a strategic agreement  with Quintiles to facilitate a higher level of clinical trial participation with an emphasis on safety, improved study efficiencies and excellent quality data in medical research. Clinical Research Advantage is the first therapeutically aligned network of Family Medicine community-based sites selected by Quintiles as a strategic alliance.

“It is an honor to be chosen by Quintiles, the world’s largest biopharmaceutical services provider with the highest standards for quality and safety,” said Mark S. Hanley, CRA’s Chief Executive Officer. “The core value and principal purpose of Clinical Research Advantage is to improve the lives of patients through the development of new medical therapies. Working with Quintiles will allow CRA to conduct an increased number of community-based trials with unparalleled accuracy and safety.”

“Clinical Research Advantage impressed us with their high standards for quality, high patient enrolments, and exceptional study start-up abilities,” said Lindy Jones, Senior Vice President, Integrated Site Services, Quintiles. “Many chronic conditions such as diabetes and heart disease are now managed in the community. It is imperative that these patient populations have the opportunity to participate in studies and be a part of the quest to develop new and better medicines for conditions that have a significant impact on both individuals and society.  We are pleased to enter into this relationship with CRA and anticipate that together we will ensure that studies start on the right path.”

The CRA-Quintiles relationship marks a new era in Phase II – IV clinical trials, enabling physicians and clinical researchers to conduct an increased number of trials across a wide range of disease areas. In addition, it will streamline and expedite the process of bringing these potentially life-changing and life-saving drugs to market.
About Clinical Research Advantage

Tempe, Arizona-based Clinical Research Advantage, Inc. (CRA) is a provider of a range of research services to pharmaceutical companies and clinical research organizations. As a leading trial management organization, CRA operates from 38 sites across 17 geographic markets nationwide, helping trial sponsors bring drugs to market more quickly and efficiently. Founded in 1992, CRA has successfully completed more than 1,800 clinical trials on behalf of its clients. For more information, please visit www.crastudies.com.

4692_CRA_f

Clinical Research Advantage VP earns Silver Stevie

Kim Kundert, RN, BSN, CCRC, has received the 2012 Silver Stevie Award for Female Executive of the Year in the Business Services category. Kundert was honored for her achievements as Vice President of Clinical Operations for Clinical Research Advantage, an integrated network of clinical trial sites.

The Stevie Awards for Women in Business are the world’s top honors for female entrepreneurs, executives, and the organizations they run. All individuals and organizations worldwide are eligible to submit nominations – public and private, for-profit and non-profit, large and small. The 2012 awards received entries from 17 nations and territories.

Stevie Award winners were selected by more than 200 executives worldwide who participated in the judging process this year.

“In 2012, Clinical Research Advantage became the largest integrated site network in the United States, and Kim Kundert has been a driving force behind the company’s rapid growth and expansion. We are thrilled that she has received national recognition for her executive leadership,” said Mark S. Hanley, CEO of Clinical Research Advantage.

This year marked the 9th Annual Celebration of the Stevie Awards for Women in Business. “This year’s Stevie Award-winning women are the most accomplished, impressive group we’ve ever had. Their stories of success will be an inspiration to women around the globe who dream of starting and growing a business and making a difference in the world,” said Michael Gallagher, president and founder of the Stevie Awards.

medical.research

Tempe’s CRA acquires Radiant Research

Tempe-based CRA Holdings, LLC announced that it has acquired Radiant Research, Inc. CRA Holdings is the company that also owns Clinical Research Advantage (CRA), another major player in the SMO market. By combining these two entities under the same investment portfolio, the organizations collectively have 57 sites with more than 550 research professionals and an aggressive plan for growth.

Over the past 15 years, Radiant Research has focused on common and chronic conditions that can be recruited from the general population. Radiant specializes in trials that require large numbers of subjects to be recruited in a short period of time, or complex trials that require specialized equipment or procedures. Radiant has large stand-alone facilities in which it conducts research; the company recruits studies primarily from an active database of over one million volunteers. CRA, on the other hand, is a practice-based organization, where 85% or greater of trial participants are recruited from the investigator’s private practice. This has allowed CRA to focus on trials where disease-state management is required. Both organizations are leaders in vaccine trial execution. The union of these two companies provides for better access to patients, an ability to conduct a diverse array of trials and broader geographic diversity.

“The Radiant platform will facilitate faster expansion of our model by utilizing the Radiant sites to help launch practice-based satellite locations in the cities where Radiant already has sites. We have grown CRA from seven to 37 sites in the last five years. In order for us to achieve our goal of 80 or 90 sites in the manner we have been doing would take us at least another five years.  The Radiant acquisition will be the catalyst for much faster growth in the next 12 months,” said Mark Hanley, CEO of CRA.

“By combining the models under one umbrella, we will be able to conduct almost every type of trial, be it point of care or studies more appropriate for a stand-alone research facility,” said Julie McHugh, CEO of Radiant Research. “We have been looking for a partner that has a shared vision for growth without any sacrifice in quality. In CRA, we have found that partner.”

The combined companies will continue to function under the names of Radiant Research and CRA, but will be looking to integrate and streamline their operations in areas where integration makes sense.

Tempe-based CRA is a provider of a range of research services to pharmaceutical companies and clinical research organizations. As a leading trial management organization, CRA operates from 37 sites across 17 geographic markets nationwide, helping trial sponsors bring drugs to market more quickly and efficiently. Founded in 1992, CRA has successfully completed more than 1,800 clinical trials on behalf of its clients. For more information, please visit www.crastudies.com.

clinical research advantage

Clinical Research Advantage Receives 5 STEVIE Awards

Tempe-based Clinical Research Advantage, a community-based network of clinical trial sites, was honored with three Silver and two Bronze STEVIE Awards at the 10th Annual American Business Awards held on June 18th in New York City. The American Business Awards are the nation’s premier business awards program. This year, more than 3,000 nominations from organizations of all sizes and in virtually every industry were submitted for consideration in a wide range of categories.

Clinical Research Advantage received the following awards:

  • The Silver Award for Company of the Year in the Pharmaceuticals category.
  • A Bronze Award for the Fastest-Growing Company of the Year in the Pharmaceuticals category.
  • David Bruggeman, CRA’s President and Chief Operating Officer, was honored with Silver Awards for Executive of the Year in both the Pharmaceuticals and the Health Products and Services categories.
  • Casey Orvin, CRA’s Vice President of Business Development and Amanda Drake, CRA’s Director of Business Development were honored with a Bronze Award for Management Team of the Year in the Pharmaceuticals Category.

“David Bruggeman, Casey Orvin, Amanda Drake and all of CRA’s employees have made 2012 a remarkable year for our company. Each employee is dedicated to our mission of enhancing patient care by bringing drugs to market more quickly and efficiently, and I would like to congratulate them on achieving this level of recognition from the STEVIE® Awards,” said Mark S. Hanley, CRA’s Chief Executive Officer.

Clinical Research Advantage, Inc. (CRA) is a provider of a range of research services to pharmaceutical companies and clinical research organizations. As a leading trial management organization, CRA operates from 33 sites across 17 geographic markets nationwide, helping trial sponsors bring drugs to market more quickly and efficiently. Founded in 1992, CRA has successfully completed more than 1,800 clinical trials on behalf of its clients. For more information, visit www.crastudies.com.

For more information about Clinical Research Advantage, visit their website at crastudies.com

clinical research advantage - vaccines

Clinical Research Advantage Earns Vaccine Industry Excellence Award

Tempe-based Clinical Research Advantage, a community-based network of clinical trial sites, has been named Best Clinical Trial Site Network by the World Vaccine Congress. The award was announced at the 2012 Vaccine Industry Excellence Awards in Washington, D.C. on April 11th. The VIE Awards celebrate the leaders, innovators and pioneers in the vaccine industry. Clinical Research Advantage also received second place for Best Clinical Trial Site.

“We are honored to win this prestigious award,” said Mark Hanley, CEO of Clinical Research Advantage. “The key to CRA’s success has been the development of research offices within community physician practices. We take pride in partnering with these established practices to provide rapid, successful enrollment that expedites the process of bringing vaccines to market.”

Casey Orvin, CRA’s Vice President of Business Development was on hand to accept the award in Washington, D.C. “It is with great honor that we accept the award for Best Clinical Trial Site Network. We are grateful to all the pharmaceutical sponsors and CROs who trust our sites and staff, time and time again, to successfully enroll in their vaccine studies. We have been fortunate, for the last several years, to be the leader in providing high quality data and rapidly enrolling sites to the vaccine industry,” said Orvin.

The Vaccine Industry Excellence Award nominees are voted on by an independent judging panel, comprised of senior industry representatives from public health organizations, non-governmental organizations, academic and research institutes, industry experts and affiliate member associations, pharmaceutical, biotech, global consultancies and press affiliates.

For more information on Clinical Research Advantage, visit Clinical Research Advantage’s website at crastudies.com.